<DOC>
	<DOCNO>NCT00832208</DOCNO>
	<brief_summary>This phase II/III open , comparative dose trial find low single dose AmBisome treatment primary , symptomatic visceral leishmaniasis ( VL ) , HIV negative patient . In trial , minimum effective dose determine sequential step , dose escalation design , minimise number patient expose low , potentially inadequate dos provide contemporaneous comparative data manufacturer 's recommend dose schedule indication .</brief_summary>
	<brief_title>Open-Label , Sequential Step , Safety Efficacy Study Determine Optimal Single Dose Ambisome Patients With VL</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Male female adult child age 4 year old upper age limit ( accordance manufacturer 's instruction ) Acute , symptomatic , VL proven parasitological examination splenic aspirate ( bone marrow aspirate ) initial parasite index least 2+ Haemoglobin &gt; 4g/dL Fever 2 week Living within reachable distance trial site enable attendance followup visit Written inform consent participate ( child , parent guardian ) HIV negative status Patients 'in extremis ' signs/symptoms indicative severe VL Patients receive antileishmanial treatment within last 6 month Patients receive investigational ( unlicensed ) drug 6 month recruitment Known underlie chronic disease , severe cardiac , pulmonary , renal , hepatic impairment . Renal function test ( serum creatinine ) outside normal range Liver function test 3 time normal range study entry Platelet count le 40,000/ mm3 Known alcohol abuse Pregnancy lactation Concomitant acute drug usage malaria bacterial infection , pneumonia within last 7 day Known hypersensitivity AmBisome amphotericin B Any condition may invalidate trial</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>